We observed a partial rescue of TGF-β-mediated reduction in the efficacy of SAR442257 by vactoserib in two primary MM cells refractory to bispecific antibodies for TC engagement (Figure 4e) and anti-CD38 therapy (Figure 4f). This evidence concerns the gene TGFB1 and Miyoshi myopathy.